Skylar Jeremias

Phase 3 data show povorcitinib delivers rapid lesion clearance in HS, improves quality of life outcomes, and offers favorable safety through 24 weeks.

Elona Toska, MSc, DPhil, explores drivers of HIV in pregnant women and young mothers: biology, relationships, and postpartum treatment drop-off.

Sweeping federal funding cuts and stalled prevention efforts are unraveling hard-won gains in HIV research and access, warns Peter Staley.

Todd Brown, MD, PhD, explains key considerations for using GLP‑1 drugs in patients with HIV, including titration tips, surgery precautions, and bone/muscle monitoring.

At CROI 2026, experts warned that missing HBV screening risks reactivation during HIV therapy switches.

The REPRIEVE study finds statins cut heart events in HIV by lowering lipids, inflammation, and hypertension risk.

Victor Appay, PhD, explains how long-term ART slows immune aging, boosting HIV viral suppression and paving the way for remission without therapy.

Doxy-PEP reshapes STI prevention, while congenital syphilis surges; experts urge scaling HIV and STI care infrastructure to improve testing and treatment access.

CROI 2026 highlights will include HIV prevention, long-acting treatments, and other advancements shaping research, clinical practice, and global policy.

City leaders share real-world GLP-1 coverage tactics, showing how public employers balance access, costs, and lasting weight-management outcomes with data-driven oversight.

The FDA granted sibeprenlimab accelerated approval for nephropathy after data showed it cut IgA nephropathy proteinuria by about 50% via APRIL inhibition.

New stroke breakthroughs spotlight faster treatment, factor XI prevention, better recovery, and the push to deliver care equitably with smart wearables.

OCEANIC-STROKE trial data show asundexian cuts ischemic stroke across subtypes with no rise in major bleeding, which could reshape antithrombotic choices.

Many older HFpEF patients appear to have CKD from aging and obesity; visceral adiposity drives kidney risk more than intrinsic damage or low eGFR.

A review updates MASH diagnosis and prognosis guidelines, highlighting noninvasive scores, imaging, and emerging therapies, plus lifestyle strategies to improve outcomes.

Ashkan Shoamanesh, MD, discusses a secondary analysis of the efficacy and safety of the factor XIa inhibitor asundexian by underlying stroke etiology.

Stroke patients face unequal access to clot-removal care; race and insurance shape transfers, even with Medicare—here’s what must change, according to Luke Messac, MD, PhD.

ED dizziness visits see rising MRI use at discharge; exam-guided imaging helps detect missed strokes and informs secondary prevention.

Stroke recovery improves when care addresses social needs like reducing loneliness and depression and strengthening support.

Shervin Badihian, MD, explains how digital health tools can help boost poststroke activity via reminders, goals, feedback, and gamification.

Rising stroke rates in young adults highlight the need to manage blood pressure and cholesterol early and improve outcomes through better ICU care.

Deaf patients face major gaps in stroke care, from poor ASL health literacy to interpreter barriers, undermining discharge understanding and emergency response.

Obesity market overview for employers: data on GLP-1s for obesity, digital solutions, and benefit strategies to control costs and outcomes.

New research highlights the effectiveness of targeted therapies for metabolic dysfunction–associated steatohepatitis (MASH), guiding treatment decisions and trial designs.

Semaglutide shows promise in improving liver health and metabolic outcomes in MASH, enhancing steatohepatitis resolution and cardiometabolic measures.

New research reveals gut microbiome changes in children with obesity signal liver disease progression, offering insights for early detection and intervention.

A systematic review reveals that cardiovascular risks emerge early in chronic kidney disease, highlighting the need for tailored management strategies.

Explore the evolving GLP-1 landscape with insights from industry experts, shaping future health strategies and plan designs for employers.

Dyslipidemia significantly impacts cardiovascular risk in chronic kidney disease, necessitating tailored lipid management strategies for optimal patient outcomes.

Researchers unveil a spatial multi-omics atlas revealing immune cell interactions and lipid metabolism's role in metabolic liver diseases, offering new therapeutic insights.